TrialHepatology communications2025

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.

Sanam Tabataba Vakili et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.